Anticonvulsants Market, by Drug Class (Barbiturates, Benzodiazepines, Hydantoins, Succinimides, and Others), by Application (Epilepsy, Migraine, Fibromyalgia, Neuropathic Pain, Anxiety, and Bipolar Disorder), by Route of Administration (Enteral, Parenteral, and Topical), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Anticonvulsants are pharmaceutical agents used for the treatment of epileptic seizures. These are commonly known as anti-epileptic drugs or anti-seizure drugs. Epilepsy is a chronic central nervous system (neurological) disorder, wherein brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Anticonvulsant drugs are also used for the treatment of bipolar disorder, borderline personality disorder, fibromyalgia, and neuropathic pain. Epilepsy can affect any individual at any age. According to Epilepsy Society of U.K. 2019 data, over 20 drugs are available for the treatment of epilepsy such as barbiturates, carboxamides, carbamates, and GABA analogs and around 25 generics are present in the market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2516

Global Anticonvulsants Market: Drivers

The anticonvulsants market size is expected to increase over the forecast period, owing to rising prevalence of epilepsy globally. According to the World Health Organization (WHO) January 2019 report, around 50 million people are affected by epilepsy worldwide. Moreover, it is estimated that around 2.4 million new cases of epilepsy are diagnosed every year, globally.

Increasing approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA) are highly contributing to increase in the anticonvulsants market revenue. There are around 24 anticonvulsants drugs approved by the FDA. In 2018, FDA approved the first drug containing an active ingredient derived from marijuana to treat rare, severe forms of epilepsy such as Lennox-Gastaut syndrome and Dravet syndrome.

Global Anticonvulsants Market: Restraints

The side effects such as sores, blisters or ulcers in mouth, excessive bleeding in wounds, stomach pain and tenderness, fever, and unusual infections, of anticonvulsants drugs is a major restraining factor for anticonvulsants market growth. According to the Epilepsy Foundation report of 2013, there are some unpredictable side effects known as idiosyncratic side effects that can be fatal, which includes serious drop in the number of white blood cells and platelets in the body, Aplastic anemia, and liver failure.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/anticonvulsants-market-2516

Global Anticonvulsants Market: Regional Analysis

North America is expected to hold dominant position in the anticonvulsants market during the forecast period, owing to increasing demand for treatment of epilepsy. For instance, according to the WHO 2019 report, in up to 70% of people living with epilepsy globally, seizure is controlled with appropriate diagnosis and use of anti-epileptic medicines. Low-cost treatment is available, with daily medication that costs US$ 5 per year.

Asia Pacific anticonvulsants market revenue is expected to witness significant growth over the forecast period, owing to increasing prevalence of epilepsy in economies such as India, China, and Japan. According to the National Center for Biotechnology Information 2015 report, India has huge patient base of 12 million people affected by epilepsy.

Global Anticonvulsants Market: Competitive Landscape

Key players operating in the global anticonvulsants market include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., UCB Group, Shire Plc., GlaxoSmithKline Plc., Cephalon Inc., and Astrazeneca Plc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2516

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737